Notice of Interest Rate on Overdue Debts, 34957 [2017-15854]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 143 / Thursday, July 27, 2017 / Notices
FOR FURTHER INFORMATION CONTACT:
Rachel Sherman, M.D., Deputy
Commissioner for Medical Products and
Tobacco, Office of Medical Products and
Tobacco, Food and Drug
Administration, White Oak Bldg. 1,
HFD–40, Room 2307, Silver Spring,
Maryland, 20993. Phone: 240–402–
4474.
SUPPLEMENTARY INFORMATION:
mstockstill on DSK30JT082PROD with NOTICES
I. Introduction
Part D, Chapter D–B, (Food and Drug
Administration), the Statement of
Organization, Functions, and
Delegations of Authority for the
Department of Health and Human
Services (35 FR 3685, February 25,
1970; 60 FR 56606, November 9, 1995;
64 FR 36361, July 6, 1999; 72 FR 50112,
August 30, 2007; 74 FR 41713, August
18, 2009; and 76 FR 45270, July 28,
2011) is amended to reflect the
reorganization of the Office of Medical
Products and Tobacco.
This reorganization establishes the
Oncology Center of Excellence (OCE) to
optimize an integrated cross-center
regulatory approach and enhance the
coordination of medical product
development in oncology. Located
within OMPT, OCE will work closely
with the directors of the centers, the
Center for Biologics Evaluation and
Research (CBER), the Center for Drug
Evaluation and Research (CDER), the
Center for Devices and Radiological
Health (CDRH), and all FDA staff
involved in oncology efforts. The OCE
will be responsible, in accordance with
an Inter-Center Agreement between
OCE, CBER, CDER, and CDRH, for the
clinical portion of medical oncology and
malignant hematology applications
involving drugs, biologics, and devices.
Other functions of the OCE include:
Harmonization of cancer-specific
regulatory approaches; coordination of
oncology-specific regulatory science
initiatives and outreach;
implementation of cross-center
oncology-focused meetings; stakeholder
engagement to the external community
of other government agencies, industry,
academia, professional societies, and
patient advocacy groups; and
communication with international
regulatory agencies.
The Food and Drug Administration
(FDA), Office of Medical Products and
Tobacco (OMPT), has been restructured
as follows:
DKK. Organization. The Office of
Medical Products and Tobacco is
headed by the Deputy Commissioner for
Medical Products and Tobacco and
includes the following organizational
units and FDA Centers that, under the
VerDate Sep<11>2014
19:17 Jul 26, 2017
Jkt 241001
current structure, officially report to
OMPT:
Office of Medical Products and Tobacco
(DKK)
Office of Special Medical Products
(DKKA)
Office of Pediatric Therapeutics
(DKKAA)
Office of Orphan Products Development
(DKKAB)
Office of Combination Products
(DKKAD)
Center for Biologics Evaluation and
Research (DKKB)
Center for Tobacco Products (DKKI)
Center for Drug Evaluation and Research
(DKKN)
Center for Devices and Radiological
Health (DKKW)
Oncology Center of Excellence (DKKX)
II. Delegations of Authority
Pending further delegation, directives,
or orders by the Commissioner of Food
and Drugs, all delegations and
redelegations of authority made to
officials and employees of affected
organizational components will
continue in them or their successors
pending further redelegations, provided
they are consistent with this
reorganization.
III. Electronic Access
This reorganization is reflected in
FDA’s Staff Manual Guide (SMG).
Persons interested in seeing the
complete Staff Manual Guide can find it
on FDA’s Web site at: https://
www.fda.gov/AboutFDA/
ReportsManualsForms/
StaffManualGuides/default.htm.
Authority: 44 U.S.C. 3101.
Dated: July 17, 2017.
Thomas E. Price,
Secretary of Health and Human Services.
[FR Doc. 2017–15443 Filed 7–26–17; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Notice of Interest Rate on Overdue
Debts
Section 30.18 of the Department of
Health and Human Services’ claims
collection regulations (45 CFR part 30)
provides that the Secretary shall charge
an annual rate of interest, which is
determined and fixed by the Secretary
of the Treasury after considering private
consumer rates of interest on the date
that the Department of Health and
Human Services becomes entitled to
recovery. The rate cannot be lower than
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
34957
the Department of Treasury’s current
value of funds rate or the applicable rate
determined from the ‘‘Schedule of
Certified Interest Rates with Range of
Maturities’’ unless the Secretary waives
interest in whole or part, or a different
rate is prescribed by statute, contract, or
repayment agreement. The Secretary of
the Treasury may revise this rate
quarterly. The Department of Health and
Human Services publishes this rate in
the Federal Register.
The current rate of 101⁄8%, as fixed by
the Secretary of the Treasury, is certified
for the quarter ended June 30, 2017.
This rate is based on the Interest Rates
for Specific Legislation, ‘‘National
Health Services Corps Scholarship
Program (42 U.S.C. 254o(b)(1)(A))’’ and
‘‘National Research Service Award
Program (42 U.S.C. 288(c)(4)(B)).’’ This
interest rate will be applied to overdue
debt until the Department of Health and
Human Services publishes a revision.
Dated: July 13, 2017.
David C. Horn,
Director, Office of Financial Policy and
Reporting.
[FR Doc. 2017–15854 Filed 7–26–17; 8:45 am]
BILLING CODE 4150–04–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Nonhuman Primate (NHP)
Core Functional Genomics Laboratory for
AIDS Vaccine Research and Development.
Date: August 31, 2017.
Time: 10:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 5601
Fishers Lane, Rockville, MD 20892
(Telephone Conference Call).
E:\FR\FM\27JYN1.SGM
27JYN1
]]>Agencies
[Federal Register Volume 82, Number 143 (Thursday, July 27, 2017)]
[Notices]
[Page 34957]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-15854]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Notice of Interest Rate on Overdue Debts
Section 30.18 of the Department of Health and Human Services'
claims collection regulations (45 CFR part 30) provides that the
Secretary shall charge an annual rate of interest, which is determined
and fixed by the Secretary of the Treasury after considering private
consumer rates of interest on the date that the Department of Health
and Human Services becomes entitled to recovery. The rate cannot be
lower than the Department of Treasury's current value of funds rate or
the applicable rate determined from the ``Schedule of Certified
Interest Rates with Range of Maturities'' unless the Secretary waives
interest in whole or part, or a different rate is prescribed by
statute, contract, or repayment agreement. The Secretary of the
Treasury may revise this rate quarterly. The Department of Health and
Human Services publishes this rate in the Federal Register.
The current rate of 10\1/8\%, as fixed by the Secretary of the
Treasury, is certified for the quarter ended June 30, 2017. This rate
is based on the Interest Rates for Specific Legislation, ``National
Health Services Corps Scholarship Program (42 U.S.C. 254o(b)(1)(A))''
and ``National Research Service Award Program (42 U.S.C.
288(c)(4)(B)).'' This interest rate will be applied to overdue debt
until the Department of Health and Human Services publishes a revision.
Dated: July 13, 2017.
David C. Horn,
Director, Office of Financial Policy and Reporting.
[FR Doc. 2017-15854 Filed 7-26-17; 8:45 am]
BILLING CODE 4150-04-P
